ChromaDex Corporation

CDXC

US1710774076

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 05/07/2024 BST			5-day change	1st Jan Change
2.51 ^USD	-1.18%		-8.06%	+75.52%

07-01	ChromaDex Joins Russell 2000 Index	MT
07-01	ChromaDex Corporation(NasdaqCM:CDXC) added to Russell Small Cap Completeness Index	CI

ChromaDex Corporation(NasdaqCM:CDXC) added to Russell 2000 Growth Index

July 30, 2024

Latest news about ChromaDex Corporation

ChromaDex Joins Russell 2000 Index	07-01	MT
ChromaDex Corporation(NasdaqCM:CDXC) added to Russell Small Cap Completeness Index	06-30	CI
ChromaDex Corporation(NasdaqCM:CDXC) added to Russell 2000 Index	06-30	CI
ChromaDex Corporation(NasdaqCM:CDXC) added to Russell 3000E Index	06-30	CI
ChromaDex Corporation(NasdaqCM:CDXC) added to Russell 3000 Growth Index	06-30	CI
ChromaDex Corporation(NasdaqCM:CDXC) added to Russell 3000E Growth Index	06-30	CI
ChromaDex Corporation(NasdaqCM:CDXC) added to Russell 2000 Growth Index	06-30	CI
ChromaDex Corporation(NasdaqCM:CDXC) added to Russell 2000 Dynamic Index	06-30	CI
ChromaDex Corporation(NasdaqCM:CDXC) added to Russell 2500 Growth Index	06-30	CI
ChromaDex Corporation(NasdaqCM:CDXC) added to Russell Small Cap Comp Growth Index	06-30	CI
ChromaDex Corporation(NasdaqCM:CDXC) added to Russell 2500 Index	06-30	CI
ChromaDex Corporation(NasdaqCM:CDXC) added to Russell 3000 Index	06-30	CI
ChromaDex Chief Financial Officer Brianna Gerber to Resign	06-25	MT
ChromaDex Says Nicotinamide Riboside Shows 'Promising Effects' in Peripheral Artery Disease Trial	06-24	MT
ChromaDex Corp Shares Results from a Milestone Phase II Clinical Study Showing the Promising Effects of Nicotinamide Riboside (NR) Supplements for People with Peripheral Artery Disease	06-24	CI
Chromadex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen®	06-13	CI
Sector Update: Health Care Stocks Higher Late Afternoon	06-07	MT
ChromaDex Says US FDA Grants NRC Orphan Drug, Rare Pediatric Disease Designations -- Shares Climb Pre-Bell	06-07	MT
Transcript : ChromaDex Corporation, Q1 2024 Earnings Call, May 08, 2024	05-08
Earnings Flash (CDXC) CHROMADEX CORPORATION Reports Q1 Revenue $22.2M, vs. Street Est of $23.6M	05-08	MT
ChromaDex Corporation Reiterates Earnings Guidance for the Full Year of 2024	05-08	CI
ChromaDex Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Chromadex Corp. Announces an Ingredient Partnership with Solgar	04-30	CI
Chromadex Announces Inaugural Major Grocery Debut of Tru Niagen® At Sprouts Farmers Market	04-23	CI
Roth MKM Raises Price Target on ChromaDex to $6 From $4.25, Keeps Buy Rating	04-09	MT

Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.

Sector

Biotechnology & Medical Research

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for ChromaDex Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.51 USD

Average target price

6.34 USD

Spread / Average Target

+152.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CHROMADEX CORPORATION	+75.52%	190M
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research